Received grant in 2018
Our newly developed "Liquid Biopsy" is a method capable of identifying men with either very high or very low risk of severe prostate cancer. The method builds upon multiple markers from samples of urine and blood.
We wish to initiate a national study to investigate the use of "Liquid Biopsy" for identifying patients with low risk of severe prostate cancer, so this group will avoid unnecessary examination, treatment and late effects. Danish Prostate Cancer Group (DaProCa) wishes to both plan and conduct the study which will primarily be taking place at Odense University Hospital.
Multidisciplinary organisation
DaProCa - Danish Prostate Cancer Group
Project stakeholders
- Lars Lund, Department of Urology, Odense University Hospital. Primary contact, mail: lars.lund@rn.dk